22 January 2015
Cercle de l'Union Interalliée
The first part of this training will cover pharmaceutical development, mature products and the special of the valuation in emerging countries.
The session will be moderated by Georges-David Medina and Damien Choplain (Bionest Finance) and Christophe Fabregue (Hyperion). During this afternoon stakeholders offer to evaluate a Specialty Pharma with both developing products in launch phase and mature.
This will be discussed in detail and describes: methodology (r) NPV sensitivity and associated tables, analyzes and transactions comparable for this product portfolio, the impact of the restatement of tax losses .I want to be present